



April 2, 2021

Pharmacy Announcement

Silver State Scripts Board Makes Changes to Preferred Drug List (PDL) Effective April 1, 2021

On January 21, 2021, the Silver State Scripts Board (SSSB) of the Nevada Department of Health and Human Services' Division of Health Care Financing and Policy met to review new and existing therapeutic drug classes on the Nevada Medicaid Preferred Drug List (PDL).

The actions taken by the committee are indicated below. All changes are effective April 1, 2021. The complete PDL is posted on the "[Preferred Drug List](#)" webpage.

Drug Class	Drugs Added As Preferred	Drugs Added As Non-Preferred
Biologic Response Modifiers, Multiple Sclerosis Agents, Injectable	None	EXTAVIA® KESIMPTA® OCREVUS®
Neurological Agents, Anticonvulsants	FINTEPLA®	APTIOM® BANZEL® BRIVIACT® KEPPRA XR® KEPPRA® SABRIL®
Neurological Agents, Anti-Migraine Agents, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists	NURTEC® ODT UBRELVY®	None
Respiratory Agents, Long acting/Maintenance Therapy	None	ARUNIVITY ELLIPTA® BREZTRI® QVAR® REDHALER